



BARBADOS REFERENCE LABORATORY LOCATIONS

- Mayfield Medical Centre, Belleville
 - Manor Lodge, Warrens
 - Sandy Crest Medical Centre
 - Maxwell Main Rd., Top Rock

Tel: (246) 436-3472 Email: info@brllimited.com Website: www.brllimited.com

View lab results, order lab test and request supplies online.

It's convenient, secure and accessible on any device, anytime.

SERVING BARBADOS
AND THE EASTERN CARIBBEAN
FOR OVER 35 YEARS









The Barbados reference laboratory now offers a quantitative detection analysis of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Spike glycoprotein antibodies. This test is useful for the identification of individuals who have an adaptive immune response to the SARS-COV-2 Spike glycoprotein by way of exposure or through vaccination.

SARS-COV-2 is an RNA virus from the family Coronaviridae, genus Betacoronavirus. All corona viruses are structurally similar using their spike proteins to enter host's cells. Spike proteins are located on the outside of the coronavirus and this is how SARS-COV-2 enters host's cells. Its location on the outside of the virus makes it the prime structural protein to be recognized by the host's immune system. The spike protein is unique to SARS-COV-2.

This assay provides a quantitative result for the presence of antibodies to the receptor binding domain on the Severe Acute Respiratory Syndrome Coronavirus 2 (SAR-COV-2) spike glycoprotein. Both vaccinated and active infections can stimulate antibodies against the Spike glycoprotein.

Negative results should be interpreted as: "No antibodies to SARS-COV-2 spike glycoprotein were detected". Please note that negative results may occur if samples are collected too early, that being, within 2 weeks of the onset of symptoms or in immunosuppressed individuals.

Positive results suggest recent or prior SARS-COV-2 infection or vaccination. No minimal antibody level or threshold has been established to indicate long term protective immunity against infection or reinfection. False positive results for IgG antibodies may occur due to cross-reactivity from pre-existing antibodies or other known causes associated with this assay.

This test is not designed for the diagnosis of SARS-COV-2. The gold standard for diagnosis according the World Health Organization and The Center for Disease Control (CDC) remains the use of a molecular method for the detection of SAR-COV-2.

Recent findings have shown that antibodies against the SARS-COV-2 are detected in over 90% of patients by two weeks after the onset of symptoms or vaccination.



Preferred: SERUM GEL TOP

Acceptable: RED TOP, EDTA OR LITHIUM HEPARIN.

Where possible, please indicate in the clinical details of the requisition form:

- 1. Vaccination status
- 2. Date of last vaccination
- 3. Past exposure (if known)